公开信息显示，现任基金经理孙浩先生:中国国籍,学历:北京大学金融硕士。从业资格:证券投资基金从 业资格,CFA。2020年7月起任汇添富基金管理股份有限公司数量分析师。2023年8月29日至今任汇添富 中证国企一带一路交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至今任中证上 海国企交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至2025年03月18日任汇添 富深证300交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至今任中证银行交易型 开放式指数证券投资基金联接基金的基金经理。2023年9月28日至今任中证长三角一体化发展主题交易 型开放式指数证券投资基金联接基金的基金经理。2023年11月28日至今任汇添富MSCI中国A50互联互 通交易型开放式指数证券投资基金联接基金的基金经理。2023年11月28日至今任汇添富中证沪港深张江 自主创新50交易型开放式指数证券投资基金的基金经理。2023年12月12日至今任汇添富上证综合交易型 开放式指数证券投资基金的基金经理。2023年12月12日至今任汇添富中证2000交易型开放式指数证券投 资基金的 ...

深圳市福田区中心五路 18 号星河中心大厦 19 层 电话：0755-23993388 传真：0755-86186205 邮编：518048 北京国枫（深圳）律师事务所 关于深圳市新产业生物医学工程股份有限公司 2024 年年度股东会的 法律意见书 国枫律股字[2025]C0047 号 致：深圳市新产业生物医学工程股份有限公司（贵公司） 北京国枫（深圳）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下简称《股东会规 则》）、《律师事务所从事证券法律业务管理办法》（以下简称《证券法律业务管理办法》）、 《律师事务所证券法律业务执业规则（试行）》（以下简称《证券法律业务执业规则》）等 相关法律、行政法规、规章、规范性文件及《深圳市新产业生物医学工程股份有限公司 章程》（以下简称《公司章程》）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见 ...

2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）本次股东会的召开情况 1、会议召集人：深圳市新产业生物医学工程股份有限公司第五届董事会 证券代码：300832 证券简称：新产业 公告编号：2025-041 深圳市新产业生物医学工程股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； （二）会议出席情况 出席本次股东会现场会议投票和网络投票的股东及股东授权委托代表共 317名，代表有表决权股份521,799,535股，占公司有表决权股份总数的66.4105%。 其中，通过现场投票的股东及股东授权委托代表 14 名，代表有表决权股份 114,452,810 股，占公司有表决权股份总数的 14.5666%；通过网络投票的股东 303 名，代表有表决权股份 407,346,725 股，占公司有表决权股份总数的 51.8438%。 出席本次股东会现场会议投票和网络投票的中小股东及股东授权委托代表 共 310 名，代表有表决权股份 82,084,485 ...

Economic Growth and Achievements - The "14th Five-Year Plan" has seen 99% of its 102 major projects and over 5,000 specific projects completed ahead of schedule [1] - China's GDP reached 134.91 trillion yuan in 2024, an increase of 31.42 trillion yuan from 2020, with an expected economic increment exceeding 30 trillion yuan during the "14th Five-Year Plan" [3] - The average GDP growth rates from 2021 to 2024 were 8.6%, 3.1%, 5.4%, and 5.0%, consistently higher than the global average [2] Industrial Development - The modern industrial system has made significant progress, with the primary industry maintaining steady growth and the secondary and tertiary industries contributing the most to GDP [4] - The added value of the equipment manufacturing and high-tech manufacturing industries grew by 7.7% and 8.9% respectively in 2024, surpassing the overall industrial growth rates [4] Emerging Industries - The "Three New" economy (new industries, new business formats, and new models) accounted for over 18% of GDP in 2024, with China leading globally in several sectors, including electric vehicles and renewable energy installations [5][6] - The digital economy's core industries contributed approximately 10% to GDP, achieving the targets set in the "14th Five-Year Plan" ahead of schedule [5][6] Trade and Export Performance - In 2024, China's total goods import and export volume reached 43.85 trillion yuan, marking a historical high and maintaining its position as the world's largest goods trader for eight consecutive years [7] - The export of mechanical and electrical products amounted to 15.12 trillion yuan in 2024, accounting for 59.43% of total exports, with significant growth in high-end equipment exports [7] - Cross-border e-commerce saw explosive growth, with imports and exports reaching 2.63 trillion yuan in 2024, a 55% increase from 2020 [8] Regional Trade Dynamics - ASEAN has become China's largest trading partner, with a trade surplus of 190.71 billion USD in 2024, reflecting a shift in trade dynamics and alignment with the "14th Five-Year Plan" goals [8]

Core Viewpoint - The high-end medical device industry in Shenzhen is a significant indicator of national manufacturing capability and technological development, with a projected revenue of 200 billion yuan by 2025, highlighting its importance in the global medical device market [1]. Group 1: Industry Overview - Shenzhen's medical device output reached 99 billion yuan in 2023, accounting for approximately 10% of the national total, with exports also around 10% [1]. - The city is home to leading companies like Mindray Medical and BGI, which are recognized among the top 100 global medical device firms [1]. Group 2: Technological Advancements - The brain-computer interface technology developed by Shenzhen Ruihan Medical has shown significant promise in rehabilitation, with patients experiencing better recovery outcomes compared to traditional methods [2][3]. - Ruihan Medical's brain-computer interface rehabilitation robot system is the first commercialized product of its kind globally, with over 100 patents and a focus on practical application [3]. Group 3: Collaborative Innovation - The National High-Performance Medical Device Innovation Center in Shenzhen is addressing core technological challenges in the medical device sector through collaborative projects with key enterprises [6][7]. - The center has successfully developed a 5.0T whole-body MRI system, marking a significant breakthrough in high-field MRI technology [6]. Group 4: Market Dynamics - The medical device industry in Shenzhen is characterized by a "chain development" model, where breakthroughs in technology stimulate growth across the entire supply chain [8]. - Companies like Mindray Medical and Libang Instruments have successfully disrupted international monopolies in their respective fields, leading to increased domestic production capabilities [9][10]. Group 5: Spatial and Policy Support - Shenzhen's medical device industry faces challenges such as limited industrial space, prompting local governments to create favorable conditions for business growth [11][12]. - The city has introduced comprehensive support measures for the medical and pharmaceutical sectors, aiming to solidify its position as a leading hub for medical device innovation [13].

Core Viewpoint - Chery Automobile emphasizes safety as a fundamental principle, launching advanced safety systems and technologies to meet the evolving demands of electric and intelligent vehicles in diverse global markets [1][2]. Group 1: Safety Initiatives - Chery has established a comprehensive safety protection system that covers all personnel, processes, conditions, and markets, aiming to redefine safety standards in the automotive industry [2]. - The company adheres to global high standards for battery safety, implementing a battery management system with ten layers of safety design and over 5,000 testing parameters, utilizing AI algorithms for real-time alerts and protection [2][4]. Group 2: Product Innovations - The "Guardian" smart safety system was unveiled, focusing on comprehensive vehicle safety across all levels, driving scenarios, and dimensions [3]. - Chery's vehicles, such as the flagship model A9L, feature advanced safety designs including a 720-degree cabin and nine airbags, showcasing the company's commitment to safety engineering [3]. Group 3: Health and Community Engagement - Chery promotes health-conscious travel with its models, ensuring a zero-odor, zero-benzene, and zero-formaldehyde environment for users [2][4]. - The launch of the "Chery Guardian Safety Club" aims to unite accident survivors, safety professionals, and public advocates to enhance safety awareness and emergency response through community initiatives [4].

证券研究报告 | 2025年05月13日 新产业（300832.SZ） 优于大市 海外业务成为核心增长驱动，流水线开始成批量装机 2024 年收入同比增长 15%，2025 年一季度收入同比增长 10%。2024 年公司 实现营收 45.35 亿（+15.4%），归母净利润 18.28 亿（+10.6%），扣非归母 净利润 17.20 亿（+11.2%）；其中单四季度营收 11.21 亿（+9.7%），归母 净利润 4.45 亿（-4.7%），在化学发光行业和同行增长承压背景下，公司收 入仍保持稳健增长。2025 年一季度公司实现营收 11.25 亿（+10.1%），归母 净利润 4.38 亿（+2.6%），在同业公司中持续表现优异。 海外业务成为核心增长驱动，流水线开始成批量装机。2024年国内收入28.43 亿（+9.32%），其中试剂收入同比增长 9.87%；国内实现发光仪装机 1641 台， 其中大型机占比 74.65%，公司延续大客户营销策略，通过 X8、X6 和 T8 等大 型仪器持续扩大三级医院客户的覆盖，推动试剂销量稳定增长。海外收入 16.84 亿（+27.67%），其中试剂收入在仪器装机量 ...

证券研究报告 | 2025年05月13日 新产业（300832.SZ） 优于大市 海外业务成为核心增长驱动，流水线开始成批量装机 海外业务成为核心增长驱动，流水线开始成批量装机。2024年国内收入28.43 亿（+9.32%），其中试剂收入同比增长 9.87%；国内实现发光仪装机 1641 台， 其中大型机占比 74.65%，公司延续大客户营销策略，通过 X8、X6 和 T8 等大 型仪器持续扩大三级医院客户的覆盖，推动试剂销量稳定增长。海外收入 16.84 亿（+27.67%），其中试剂收入在仪器装机量持续攀升的带动下同比增 长 26.47%；海外销售发光仪 4,017 台，中大型高端机型占比提升至 67.16%， 公司已构建起显著的海外品牌优势，通过"区域化运营+本地化深耕"双轮 驱动。2025 年一季度国内业务受省际联盟集采深化影响，同比增长 0.11%； 海外业务维持高增长，同比增速达 27.03%。公司自主研发的 T8 流水线上市 首年即实现全球装机 87 条的亮眼成绩，25Q1 销售/装机 39 条。 2024 年毛净利率有所下滑，各项费用率较为稳定。2024 年公司毛利率为 72.07%（-0. ...

5月13日，第一财经记者从知情人士独家获悉，荣耀在近期已完成对中国地区部关键岗位的人员部署， 其中涉及38个中国区关键岗位主管，采用"重新竞聘上岗"的方式。 这场被内部称为"雄鹰计划"的人员调整计划面向荣耀的国内外全体员工。上述知情人士透露，竞聘目前 已经完成，其中45%的岗位负责人有所调整，90后占比达到24%。 此外，记者了解到，荣耀内部新增AI新产业部门，同时将AI相关研发工作设定为一级研发部门，而在 两个月前，荣耀曾宣布将在未来五年投入超过100亿美元建设AI终端生态。 中国区关键岗位重新"竞聘" 今年1月，荣耀官宣换帅，由李健任荣耀CEO。根据公开资料显示，李健于2021年加入荣耀，曾任副董 事长、董事等职务，并长期担任人力资源部总裁和荣耀管理团队核心成员。 "核心管理队伍稳定后，公司内部开始对中国区关键岗位进行重新部署，一方面中国区是荣耀实现全球 布局的大本营，另一方面竞争最为激烈的市场需要更灵活的组织架构来应对。"上述知情人士对记者表 示，在上任的三个多月里，李健启动"雄鹰计划"，这一计划主要面向中国地区部的关键岗位，进行人员 调整。 "38个岗位更换了17个，里面既有荣耀的老将，也有很多年轻人 ...

Core Viewpoint - The recent policy announced by Trump to align U.S. drug prices with the lowest global prices could lead to a significant decrease in prescription drug prices in the U.S., potentially by 30% to 80%, raising concerns among pharmaceutical companies, especially those exporting to the U.S. [1][2] Group 1: Market Performance - As of May 13, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 2.42%, with notable increases in stocks such as BeiGene (06160) up 4.15% and Innovent Biologics (01801) up 3.14% [1] - The Hong Kong Pharmaceutical ETF (159718) opened high and increased by 2.04%, with a latest price of 0.70 yuan, and a one-month cumulative increase of 3.32% [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) increased by 0.87%, with stocks like East China Pharmaceutical (000963) rising by 2.23% [4] Group 2: Trading Volume and Liquidity - The Hong Kong Pharmaceutical ETF had a turnover of 1.72% during the trading session, with a transaction volume of 4.0999 million yuan, and an average daily transaction volume of 95.7602 million yuan over the past month [1] - The latest scale of the Medical Innovation ETF (516820) reached 1.588 billion yuan [4] Group 3: Index Composition - The top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index accounted for 60.54% of the index, including BeiGene (06160) and WuXi Biologics (02269) [5] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represented 66.51% of the index, featuring companies like Hengrui Medicine (600276) and WuXi AppTec (603259) [8]